EULAV Asset Management Has $45.35 Million Stock Holdings in Stryker Corporation (NYSE:SYK)

EULAV Asset Management grew its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 1.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 121,813 shares of the medical technology company's stock after buying an additional 2,300 shares during the period. EULAV Asset Management's holdings in Stryker were worth $45,345,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Stryker by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock worth $11,773,213,000 after buying an additional 252,188 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Stryker by 0.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock worth $4,000,056,000 after purchasing an additional 54,693 shares during the last quarter. FMR LLC lifted its holdings in shares of Stryker by 10.0% in the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after purchasing an additional 727,850 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Stryker by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock worth $2,539,033,000 after purchasing an additional 168,436 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Stryker in the 4th quarter worth approximately $1,710,744,000. Institutional investors own 77.09% of the company's stock.

Analyst Ratings Changes

SYK has been the topic of several recent research reports. Needham & Company LLC reissued a "buy" rating and issued a $442.00 price target on shares of Stryker in a report on Friday, March 21st. Wall Street Zen downgraded Stryker from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Citigroup reissued a "buy" rating and issued a $455.00 price target (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Sanford C. Bernstein set a $450.00 target price on Stryker in a research note on Monday, May 5th. Finally, BTIG Research set a $403.00 target price on Stryker and gave the company a "buy" rating in a research note on Monday, April 14th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Stryker currently has a consensus rating of "Moderate Buy" and a consensus target price of $427.30.

Stryker Price Performance

Shares of NYSE SYK traded down $3.02 during mid-day trading on Monday, reaching $392.26. The company had a trading volume of 1,310,299 shares, compared to its average volume of 1,348,084. The company has a current ratio of 1.64, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69. The stock has a market cap of $149.72 billion, a PE ratio of 53.01, a P/E/G ratio of 2.98 and a beta of 0.91. The company has a 50-day moving average price of $382.92 and a two-hundred day moving average price of $376.39. Stryker Corporation has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The company's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.50 EPS. On average, equities analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker's payout ratio is 45.41%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director owned 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 5.20% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.